Alessandro Passardi

4.5k total citations
138 papers, 2.2k citations indexed

About

Alessandro Passardi is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alessandro Passardi has authored 138 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Oncology, 47 papers in Cancer Research and 41 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alessandro Passardi's work include Colorectal Cancer Treatments and Studies (74 papers), Cancer Genomics and Diagnostics (32 papers) and Genetic factors in colorectal cancer (27 papers). Alessandro Passardi is often cited by papers focused on Colorectal Cancer Treatments and Studies (74 papers), Cancer Genomics and Diagnostics (32 papers) and Genetic factors in colorectal cancer (27 papers). Alessandro Passardi collaborates with scholars based in Italy, France and United States. Alessandro Passardi's co-authors include Paola Ulivi, Giovanni Luca Frassineti, Dino Amadori, Giorgia Marisi, Emanuela Scarpi, Martina Valgiusti, Chiara Molinari, Matteo Canale, Angela Ragazzini and Andrea Casadei‐Gardini and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Alessandro Passardi

129 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alessandro Passardi Italy	23	1.5k	681	497	488	390	138	2.2k
Riccardo Giampieri Italy	26	1.3k 0.8×	583 0.9×	687 1.4×	702 1.4×	256 0.7×	122	2.2k
Jean‐Pierre Lotz France	26	1.6k 1.1×	447 0.7×	347 0.7×	699 1.4×	698 1.8×	119	2.8k
Smitha Krishnamurthi United States	25	2.2k 1.5×	547 0.8×	834 1.7×	939 1.9×	487 1.2×	126	3.3k
Maria Carmela Piccirillo Italy	26	1.2k 0.8×	408 0.6×	502 1.0×	787 1.6×	223 0.6×	94	2.3k
Matias Riihimäki Sweden	12	1.4k 0.9×	295 0.4×	348 0.7×	821 1.7×	460 1.2×	12	2.2k
Christina Wu United States	29	2.2k 1.5×	549 0.8×	561 1.1×	725 1.5×	650 1.7×	168	3.1k
Erika Martinelli Italy	23	2.2k 1.4×	577 0.8×	629 1.3×	859 1.8×	595 1.5×	86	3.4k
Herbert H. Loong Hong Kong	30	1.5k 1.0×	548 0.8×	790 1.6×	1.3k 2.7×	412 1.1×	163	3.0k
H. Samonigg Austria	26	1.8k 1.2×	905 1.3×	379 0.8×	482 1.0×	349 0.9×	72	2.7k
Rajesh Ramanathan United States	24	1.1k 0.7×	306 0.4×	785 1.6×	465 1.0×	467 1.2×	87	2.3k

Countries citing papers authored by Alessandro Passardi

Since Specialization

Citations

This map shows the geographic impact of Alessandro Passardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandro Passardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandro Passardi more than expected).

Fields of papers citing papers by Alessandro Passardi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessandro Passardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandro Passardi. The network helps show where Alessandro Passardi may publish in the future.

Co-authorship network of co-authors of Alessandro Passardi

This figure shows the co-authorship network connecting the top 25 collaborators of Alessandro Passardi. A scholar is included among the top collaborators of Alessandro Passardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandro Passardi. Alessandro Passardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Landi, M. T., Chiara Cremolini, Sara Lonardi, et al.. (2025). Switch from cetuximab to panitumumab during encorafenib-based therapy in BRAF V600E mutated metastatic colorectal cancer: An international multicenter analysis from the AGEO group. Clinics and Research in Hepatology and Gastroenterology. 50(1). 102746–102746.

Moretto, Roberto, Daniele Rossini, Carlotta Antoniotti, et al.. (2025). The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies. European Journal of Cancer. 222. 115470–115470.

Moretto, Roberto, Sabina Murgioni, Marco Maria Germani, et al.. (2024). KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration. JCO Precision Oncology. 8(8). e2400329–e2400329. 1 indexed citations

Petracci, Elisabetta, Alessandro Passardi, Annibale Biggeri, et al.. (2024). Baseline and Longitudinal Neutrophil-to-Lymphocyte Ratio as Prognostic Factor for Metastatic Colorectal Cancer: A Secondary Analysis of the ITACa Randomized Trial. JCO Precision Oncology. 8(8). e2300256–e2300256. 1 indexed citations

Germani, Marco Maria, Rossana Intini, Maria Bensi, et al.. (2024). Treatment of patients with BRAF-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset. ESMO Open. 9(4). 102996–102996. 4 indexed citations

Marmorino, Federica, Gianmarco Piccinno, Daniele Rossini, et al.. (2023). Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study.. Journal of Clinical Oncology. 41(16_suppl). 3534–3534. 2 indexed citations

Passardi, Alessandro, Alessandro Bittoni, Giorgia Marisi, et al.. (2023). Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab. Therapeutic Advances in Medical Oncology. 15. 2656920–2656920. 10 indexed citations

Passardi, Alessandro, Flavia Foca, Orazio Caffo, et al.. (2022). A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training–Validation Trial. Journal of Medical Internet Research. 24(1). e27349–e27349. 4 indexed citations

Passardi, Alessandro, Patrizia Serra, Orazio Caffo, et al.. (2022). Use of the ONCO-TreC electronic diary compared with a standard paper diary to improve adherence to oral cancer therapy in patients with solid and haematological tumours: protocol for a randomised controlled trial. BMJ Open. 12(1). e055814–e055814. 1 indexed citations

10.

Passardi, Alessandro, Ilario Giovanni Rapposelli, Emanuela Scarpi, et al.. (2021). Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies. Biomolecules. 11(8). 1200–1200. 3 indexed citations

11.

Passardi, Alessandro, Patrizia Serra, Caterina Donati, et al.. (2021). An Integrated Model to Improve Medication Reconciliation in Oncology: Prospective Interventional Study. Journal of Medical Internet Research. 23(12). e31321–e31321. 1 indexed citations

12.

Passardi, Alessandro, Emanuela Scarpi, & Paola Ulivi. (2021). Special Issue on Molecular and Translational Research on Colorectal Cancer 2.0. International Journal of Molecular Sciences. 22(14). 7479–7479. 1 indexed citations

13.

Monti, Manlio, Ilaria Massa, Flavia Foca, et al.. (2020). Retrospective analysis of gastric cancer management in a real-world setting: a single-institution experience. Tumori Journal. 106(2). 165–171. 1 indexed citations

14.

Passardi, Alessandro, Emanuela Scarpi, Elisa Neri, et al.. (2019). Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Cancers. 11(5). 663–663. 9 indexed citations

15.

Casadei‐Gardini, Andrea, Emanuela Scarpi, Elena Orlandi, et al.. (2018). Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial. OncoTargets and Therapy. Volume 11. 5261–5268. 10 indexed citations

16.

Ulivi, Paola, Matteo Canale, Alessandro Passardi, et al.. (2018). Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. International Journal of Molecular Sciences. 19(1). 307–307. 62 indexed citations

17.

Molinari, Chiara, Giorgia Marisi, Alessandro Passardi, et al.. (2018). Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?. International Journal of Molecular Sciences. 19(12). 3733–3733. 154 indexed citations

18.

Ulivi, Paola, Emanuela Scarpi, Elisa Chiadini, et al.. (2017). Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy. International Journal of Molecular Sciences. 18(6). 1240–1240. 39 indexed citations

19.

Passardi, Alessandro, Emanuela Scarpi, Stefano Tamberi, et al.. (2015). Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. PLoS ONE. 10(8). e0134732–e0134732. 35 indexed citations

20.

Milandri, Carlo, R. Polico, Domenico Garcea, et al.. (2011). GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer.. PubMed. 58(106). 20–21. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact